Janssen to Present New Simeprevir Data at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL)

Plug, Ireland, March 24, 2014/PRNewswire/ - New information from the clinical advancement program for Janssen's protease inhibitor simeprevir in the treatment of genotype 1 ceaseless hepatitis C infection (HCV) in grown-up patients with repaid liver ailment will be exhibited at The International Liver Congress™ of the European Association for the Liver's investigation (EASL). The International Liver Congress™ 2014 will occur from April 9-13 in London.

Janssen will show oral and blurb presentations spreading over the organization's Phase 2 and Phase 3 improvement program for simeprevir in treatment blends with and without ribavirin and interferon. The presentations incorporate last information from the Phase 2 COSMOS investigation of simeprevir in blend with Gilead Sciences Inc's. nucleotide inhibitor sofosbuvir, with and without ribavirin, which will be displayed amid oral sessions.

The information to be displayed at the International Liver Congress™ 2014 include:

Late-Breaking Oral Presentation

Simeprevir in addition to sofosbuvir with/without ribavirin in HCV genotype 1 earlier invalid responder/treatment-gullible patients (COSMOS Study): essential endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2)

Lead Author: Eric Lawitz; The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX

Oral Presentations

When every day simeprevir (TMC435) in addition to sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 former invalid responders with METAVIR F0-2: COSMOS Study Cohort 1 subgroup investigation

Lead Author: Mark Sulkowski; Johns Hopkins University School of Medicine, Baltimore, MD

Blurb Presentations

Simeprevir decreases time with peginterferon/ribavirin-instigated indications and personal satisfaction weaknesses: 72-week results from three Phase 3 thinks about

Lead Author: Jane Scott; Janssen

Virology examinations of simeprevir in Phase 2b and 3 contemplates

Lead Author: Oliver Lenz; Janssen

Profound sequencing examinations of minority benchmark polymorphisms and industriousness of developing transformations in HCV genotype 1-contaminated patients treated with simeprevir

Lead Author: Bart Fevery; Janssen

Full session points of interest and information presentation postings for The International Liver Congress™ 2014 can be found at http://www.ilc-congress.eu.

About simeprevir

Simeprevir is a NS3/4A protease inhibitor together created by Janssen R&D Ireland and Medivir AB and showed for the treatment of unending hepatitis C contamination in mix with pegylated interferon and ribavirin in HCV genotype 1 tainted patients with remunerated liver ailment, including cirrhosis.

Janssen is in charge of the worldwide clinical improvement of simeprevir and has restrictive, overall promoting rights, with the exception of in the Nordic nations. Medivir AB will hold promoting rights for simeprevir in these nations under the advertising approval held by Janssen-Cilag International NV. Simeprevir was sanction for the treatment of genotype 1 hepatitis C in September 2013 in Japan and in November 2013 in Canada and the U.S. A Marketing Authorisation Application was submitted to the European Medicines Agency (EMA) in April 2013 by Janssen-Cilag International NV looking for endorsement of simeprevir for the treatment of genotype 1 or genotype 4 unending hepatitis C and The Committee for Medicinal Products for Human Use (CHMP) has embraced a positive conclusion, prescribing Marketing Authorisation in the European Union for the utilization of simeprevir in blend with other restorative items for the treatment of ceaseless HCV. This application is under survey by the EMA.

About Hepatitis C

Hepatitis C, a blood-borne irresistible sickness of the liver and a main source of constant liver infection, is the center of a quickly advancing treatment scene. Around 150 million individuals are contaminated with hepatitis C overall and 350,000 individuals for every beyond words the sickness internationally. At the point when left untreated, hepatitis C can bring about critical harm to the liver including cirrhosis. Moreover, hepatitis C may build the danger of creating confusions from cirrhosis, which may incorporate liver disappo